Securities code: Zhejiang Jingxin Pharmaceutical Co.Ltd(002020) securities abbreviation: Zhejiang Jingxin Pharmaceutical Co.Ltd(002020) Announcement No.: 2022010 Zhejiang Jingxin Pharmaceutical Co.Ltd(002020)
Announcement on stock price changes
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Abnormal fluctuation of stock trading
Zhejiang Jingxin Pharmaceutical Co.Ltd(002020) (hereinafter referred to as "the company") the stock trading price deviated from the closing price for two consecutive trading days on March 24 and March 25, 2022 by more than 20%. According to the trading rules of Shenzhen Stock Exchange and other relevant regulations, it belongs to the situation of abnormal fluctuation of stock trading.
2、 The company pays attention to and verifies relevant information
In view of the abnormal fluctuation of the company's stock trading, the company has checked the relevant matters, and the relevant information is explained as follows:
1. The information disclosed by the company in the early stage does not need to be corrected or supplemented.
2. Recently, the company noticed rumors on the Internet that "the company has the API of covid-19 of trifluorobenzoyl chloride" and " Zhejiang Jingxin Pharmaceutical Co.Ltd(002020) two cities have the only target of yanyeyi / Pfizer covid-19 key intermediate at the same time". At present, co19-pfizer, a subsidiary of norubicin, is mainly engaged in clarifying the raw materials of norubicin and Pfizer, and has no cooperation with norubicin. The 2,4,5-trifluorobenzoyl chloride planned by the company's Shandong base is the key intermediate for the preparation of 2,4,5-trifluorobenzene, and it still needs a certain period to be put into operation. It is expected that it will have no material impact on the company's performance in 2022, and there is great uncertainty about the impact on the company's future annual performance. The company will continue to pay close attention to the progress of covid-19 therapeutic drugs outside China and make prudent decisions according to the changes of market demand. Please pay attention to investment risks and invest rationally.
3. Recently, the company's business situation and internal and external business environment have not changed significantly.
4. The company, controlling shareholders and persons acting in concert do not have any major matters that should be disclosed but not disclosed about the company, or major matters in the planning stage.
5. The controlling shareholders and persons acting in concert of the company did not buy or sell the company's shares during the abnormal fluctuation of the company's stock trading.
6. Through self-examination, the company has no other circumstances in violation of the provisions on fair information disclosure.
3、 Whether there is a description of the information that should be disclosed but not disclosed
The board of directors of the company confirms that the company has no undisclosed matters or planning, negotiation, intention, agreement, etc. related to the matters that should be disclosed in accordance with the relevant provisions of the Listing Rules of Shenzhen Stock Exchange; The board of directors has not been informed that the company has undisclosed information that has a great impact on the trading price of the company's shares and their derivatives that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange and other relevant provisions; The information disclosed by the company in the early stage does not need to be corrected or supplemented.
4、 Risk tips
1. Through self-examination, the company does not violate the fair disclosure of information.
2. The company disclosed the 2021 annual performance forecast (Announcement No.: 2022008) on February 26, 2022. As of the disclosure date of this announcement, the above performance is not expected to be corrected. The specific financial data of the company in 2021 shall be subject to the annual report of the company in 2021. The undisclosed regular performance information of the company is not provided to any third party other than the accounting firm audited by the company.
3. The company solemnly reminds investors: securities times, China Securities News and cninfo（ http://www.cn.info.com.cn. ）As the information disclosure media designated by the company, all information of the company shall be subject to the information published in the above designated media. Please invest rationally and pay attention to risks.
It is hereby announced.
Zhejiang Jingxin Pharmaceutical Co.Ltd(002020) board of directors March 28, 2022
